• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

中医药在心血管疾病中的转化研究与临床应用

Translational Research and Clinical Application of Traditional Chinese Medicine in Cardiovascular Diseases.

作者信息

Cheang Iokfai, Chen Ziqi, Zhu Xu, Wang Tongxin, Chang Liping, Gao Rongrong, Jia Zhenhua, Li Xinli

机构信息

State Key Laboratory for Innovation and Transformation of Luobing Theory, Department of Cardiology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, China.

State Key Laboratory for Innovation and Transformation of Luobing Theory, Shijiazhuang New Drug Technology Innovation Center of Compound Traditional Chinese Medicine, Shijiazhuang, China.

出版信息

JACC Asia. 2024 Sep 17;4(10):711-720. doi: 10.1016/j.jacasi.2024.07.012. eCollection 2024 Oct.

DOI:10.1016/j.jacasi.2024.07.012
PMID:39553906
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11561486/
Abstract

Luobing theory is based on the principles of traditional Chinese medicine (TCM) and focuses on the regulation of blood circulation. The translation of Luobing theory into clinical practice has shown promising results in the treatment of cardiovascular diseases (CVDs). Studies have reported the benefits of using Luobing theory in the treatment of metabolic syndrome, atherosclerosis, arrhythmia, and heart failure. This review article provides an overview of the evidence-based application of TCM Luobing theory in the treatment of CVDs. It also highlights the challenges and opportunities of translating TCM into clinical practice and provides valuable insights for future CVD research.

摘要

络病理论基于中医原理,专注于血液循环的调节。络病理论在心血管疾病(CVD)治疗中的临床实践转化已显示出令人鼓舞的结果。研究报告了络病理论在治疗代谢综合征、动脉粥样硬化、心律失常和心力衰竭方面的益处。这篇综述文章概述了中医络病理论在心血管疾病治疗中的循证应用。它还强调了中医临床实践转化面临的挑战与机遇,并为未来心血管疾病研究提供了有价值的见解。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f0cf/11561486/47afc3dd8e90/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f0cf/11561486/47afc3dd8e90/ga1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f0cf/11561486/47afc3dd8e90/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f0cf/11561486/47afc3dd8e90/ga1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f0cf/11561486/47afc3dd8e90/gr1.jpg

相似文献

1
Translational Research and Clinical Application of Traditional Chinese Medicine in Cardiovascular Diseases.中医药在心血管疾病中的转化研究与临床应用
JACC Asia. 2024 Sep 17;4(10):711-720. doi: 10.1016/j.jacasi.2024.07.012. eCollection 2024 Oct.
2
Shensong yangxin, a multi-functional traditional Chinese medicine for arrhythmia: A review of components, pharmacological mechanisms, and clinical applications.参松养心——一种用于治疗心律失常的多功能中药:成分、药理机制及临床应用综述
Heliyon. 2024 Aug 2;10(16):e35560. doi: 10.1016/j.heliyon.2024.e35560. eCollection 2024 Aug 30.
3
Tongxinluo capsule as a multi-functional traditional Chinese medicine in treating cardiovascular disease: A review of components, pharmacological mechanisms, and clinical applications.通心络胶囊作为治疗心血管疾病的多功能中药:成分、药理机制及临床应用综述
Heliyon. 2024 Jun 21;10(13):e33309. doi: 10.1016/j.heliyon.2024.e33309. eCollection 2024 Jul 15.
4
Study protocol: Traditional Chinese Medicine (TCM) syndrome differentiation for heart failure patients and its implication for long-term therapeutic outcomes of the Qiliqiangxin capsules.研究方案:心力衰竭患者的中医证候辨证及其对芪苈强心胶囊长期治疗效果的影响
Chin Med. 2021 Oct 16;16(1):103. doi: 10.1186/s13020-021-00515-1.
5
Tongxinluo capsule as supplementation and cardiovascular endpoint events in patients with coronary heart disease: A systematic review and meta-analysis of randomized, double-blind, placebo-controlled trials.通心络胶囊作为冠心病患者的补充治疗和心血管终点事件:一项随机、双盲、安慰剂对照试验的系统评价和荟萃分析。
J Ethnopharmacol. 2022 May 10;289:115033. doi: 10.1016/j.jep.2022.115033. Epub 2022 Jan 26.
6
Recent advances of traditional Chinese medicine against cardiovascular disease: overview and potential mechanisms.中医药防治心血管疾病的研究进展:概述与潜在机制。
Front Endocrinol (Lausanne). 2024 Sep 30;15:1366285. doi: 10.3389/fendo.2024.1366285. eCollection 2024.
7
Integrating Evidence of the Traditional Chinese Medicine Collateral Disease Theory in Prevention and Treatment of Cardiovascular Continuum.整合中医络病理论在心血管连续体防治中的证据
Front Pharmacol. 2022 Mar 15;13:867521. doi: 10.3389/fphar.2022.867521. eCollection 2022.
8
The discovery of Q-markers of Qiliqiangxin Capsule, a traditional Chinese medicine prescription in the treatment of chronic heart failure, based on a novel strategy of multi-dimensional "radar chart" mode evaluation.基于多维“雷达图”模式评价的新策略发现芪苈强心胶囊治疗慢性心力衰竭的 Q 标志物:一项中药方剂研究。
Phytomedicine. 2021 Feb;82:153443. doi: 10.1016/j.phymed.2020.153443. Epub 2020 Dec 23.
9
Traditional Chinese Medicine-based Treatment in Cardiovascular Disease: Potential Mechanisms of Action.基于中医药的心血管病治疗:作用机制探讨。
Curr Pharm Biotechnol. 2024;25(17):2186-2199. doi: 10.2174/0113892010279151240116103917.
10
Traditional Chinese medicine and mitophagy: A novel approach for cardiovascular disease management.传统中医与线粒体自噬:心血管疾病治疗的新策略
Phytomedicine. 2024 Jun;128:155472. doi: 10.1016/j.phymed.2024.155472. Epub 2024 Feb 24.

本文引用的文献

1
The traditional Chinese medicine Qiliqiangxin in heart failure with reduced ejection fraction: a randomized, double-blind, placebo-controlled trial.中药芪苈强心胶囊治疗射血分数降低的心力衰竭:一项随机、双盲、安慰剂对照试验。
Nat Med. 2024 Aug;30(8):2295-2302. doi: 10.1038/s41591-024-03169-2. Epub 2024 Aug 2.
2
Jinlida for Diabetes Prevention in Impaired Glucose Tolerance and Multiple Metabolic Abnormalities: The FOCUS Randomized Clinical Trial.金利达在糖耐量受损和多种代谢异常人群中的糖尿病预防作用:聚焦随机临床试验。
JAMA Intern Med. 2024 Jul 1;184(7):727-735. doi: 10.1001/jamainternmed.2024.1190.
3
JinLiDa granules alleviates cardiac hypertrophy and inflammation in diabetic cardiomyopathy by regulating TP53.
金利达颗粒通过调节 TP53 减轻糖尿病心肌病中的心肌肥厚和炎症。
Phytomedicine. 2024 Jul 25;130:155659. doi: 10.1016/j.phymed.2024.155659. Epub 2024 May 10.
4
2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.2023 ACC/AHA/ACCP/HRS 指南:心房颤动的诊断与管理——美国心脏病学会/美国心脏协会联合临床实践指南委员会的报告。
J Am Coll Cardiol. 2024 Jan 2;83(1):109-279. doi: 10.1016/j.jacc.2023.08.017. Epub 2023 Nov 30.
5
Qiliqiangxin: A multifaceted holistic treatment for heart failure or a pharmacological probe for the identification of cardioprotective mechanisms?芪苈强心:心力衰竭的多方位整体治疗,还是心脏保护机制的药理学探索?
Eur J Heart Fail. 2023 Dec;25(12):2130-2143. doi: 10.1002/ejhf.3068. Epub 2023 Nov 14.
6
Traditional Chinese Medicine Meets Evidence-Based Medicine in the Acutely Infarcted Heart.中医与急性心肌梗死中的循证医学相遇。
JAMA. 2023 Oct 24;330(16):1529-1530. doi: 10.1001/jama.2023.20838.
7
Traditional Chinese Medicine Compound (Tongxinluo) and Clinical Outcomes of Patients With Acute Myocardial Infarction: The CTS-AMI Randomized Clinical Trial.中药复方(通心络)对急性心肌梗死患者临床结局的影响:CTS-AMI 随机临床试验。
JAMA. 2023 Oct 24;330(16):1534-1545. doi: 10.1001/jama.2023.19524.
8
2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure.《2021年欧洲心脏病学会急性和慢性心力衰竭诊断与治疗指南》2023年聚焦更新
Eur Heart J. 2023 Oct 1;44(37):3627-3639. doi: 10.1093/eurheartj/ehad195.
9
2023 ESC Guidelines for the management of acute coronary syndromes.2023年欧洲心脏病学会急性冠状动脉综合征管理指南。
Eur Heart J. 2023 Oct 12;44(38):3720-3826. doi: 10.1093/eurheartj/ehad191.
10
No reflow phenomenon in CAD patients after percutaneous coronary intervention: A prospective hospital based observational study.经皮冠状动脉介入治疗后 CAD 患者无无复流现象:一项前瞻性基于医院的观察性研究。
Indian Heart J. 2023 Mar-Apr;75(2):156-159. doi: 10.1016/j.ihj.2023.02.002. Epub 2023 Feb 11.